Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects with Advanced High Grade Serous Ovarian Cancer


Collapse Overview 
Collapse sponsor award id
SOVI-2302


Collapse Biography 

Collapse Time 
Collapse start date
2024-09-26

Collapse end date
2034-09-25